Skip to content
Monday 10 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,901.09
+0.31%
DAX
26,319.45
+0.69%
CAC 40
8,714.93
+0.17%
STOXX 50
6,523.86
+0.33%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Thursday 07 August 2014 4:50 pm  |  Updated:  Friday 07 June 2019 2:13 am

Philip Hampton is being lined up to replace Sir Christopher Gent as GSK’s next chairman

By: Lynsey Barber

Add as a preferred source on Google

Sir Philip Hampton is being lined up to take the role of chairman at Britain’s biggest drug company Glaxosmithkline after exiting Royal Bank of Scotland, Sky News reports.

It’s said that Hampton will join GSK as early as next month as a non-executive director or deputy chairman, moving into the chairman’s seat by 2015.

GSK’s current chairman Christopher Gent has previously stated his intention to announce a successor this year with a view to standing down next year after a decade in charge.

Hampton was parachuted into the bailed-out bank in 2009 in to help turn it around and was previously chairman of Sainsbury’s. Hampton has also been finance director at some of the UK’s leading firms, including BT, Lloyds bank and British Gas.

RBS declined to comment and GSK declined to comment.

Update: This story was updated to say that GSK declined to comment.

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • Company
  • GSK

Trending Articles

  • Burnham facing calls to cut employment red tape as job seekers grow for 41 months

  • Government to inject millions into electric vehicle firms despite mandate backlash

  • Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera

  • Stop burying us in swollen corporate reports, says audit watchdog boss

  • Hargreaves Lansdown orders staff back to office

More from Morning Wire

  • Tate & Lyle faces shareholder revolt over executive pay

    Retail
    Tate & Lyle logo, a global food ingredients supplier, on a corporate building.
  • Sweeping job cuts at GSK to fund £400m Cambridge campus

    Pharma
    Modern GSK Cambridge campus buildings with sky bridge, green spaces, and people walking and cycling.
  • Global advisory giant Brunswick explores capital raise

    Advisory
    Alan Parker speaking at a business forum, gesturing with hands, blue background with NIKKEI and FORUM visible
  • Farage quits to stand in ‘people versus establishment’ by-election

    Politics
    George Cottrell and Nigel Farage engaging in a conversation at a political event, both dressed in formal attire.
  • UK fintech Starling to axe 130 roles in AI-powered simplification drive

    Fintech
    Starling Bank integrates Apple Pay 2022, showcasing digital banking innovation and seamless mobile payment solutions
  • SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO

    Business Wire
  • Nationwide rebel claims he was offered sweetener to drop boardroom bid

    Banking
    Nationwide has been slapped with a fine by the City watchdog.
  • Naser Taher, Chairman and Founder of MultiBank Group, Honored by H.H. Sheikh Nahyan bin Mubarak Al Nahyan with the Golden Excellence Award for FinTech, Digital Asset and Blockchain Excellence

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook